Brief: Alto Neuroscience Initiates Phase 2 Study Of Alto-101 In Cognitive Impairment Associated With Schizophrenia
20/06/2024 13:42
June 20 (Reuters) - Alto Neuroscience Inc ANRO.N :
* ALTO NEUROSCIENCE INITIATES PHASE 2 STUDY OF ALTO-101, A
NOVEL
PDE4 INHIBITOR, IN COGNITIVE IMPAIRMENT ASSOCIATED WITH
SCHIZOPHRENIA
* ALTO NEUROSCIENCE INC: EXPECTS TO REPORT TOP-LINE DATA
FROM
PHASE 2 STUDY IN SECOND HALF OF 2025
Source text for Eikon: ID:nBwFvQcMa
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements